Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoGenex/Teva Alter Late-Stage Custirsen Program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.

You may also be interested in...



Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC

The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.

Zytiga Study Supports Expansion To Early Patient Population

J&J halts Phase III trial of its prostate cancer drug six months early based on the recommendation of the trial’s independent data monitoring committee.

Prostate Cancer Market Snapshot: More Than Provenge

The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel